Core Viewpoint - 石四药集团 reported a significant decline in its mid-year performance for 2025, with a notable drop in sales revenue and profit margins, indicating potential challenges in its business operations [1] Financial Performance - The company's sales revenue for the first half of 2025 was approximately 2.147 billion HKD, representing a year-on-year decrease of about 35.7% [1] - The profit attributable to equity holders was around 283.5 million HKD, down approximately 58.7% year-on-year [1] - Earnings per share were reported at 0.0962 HKD, with an interim dividend of 0.05 HKD, compared to 0.08 HKD in the same period last year [1] Business Segments - In the infusion business, the overall sales volume decreased significantly, with approximately 715 million bottles (bags) sold, a year-on-year decline of 37%, and sales revenue of 1.199 billion HKD, down 45% [1] - For the water injection segment, the sales volume of ampoule water injections was 17.818 million units, showing a year-on-year increase of 7%, but the sales revenue fell to 157 million HKD, a decrease of 57% [1] - The oral formulation segment achieved sales revenue of 296 million HKD, reflecting a year-on-year growth of 16% [1] - In the active pharmaceutical ingredients segment, sales revenue was 361 million HKD, down 9.6% year-on-year [1]
港股异动 | 石四药集团(02005)午后跌超5% 上半年纯利同比下降58.7% 中期息减至5港仙